

HR 6092

Veteran's Prostate Cancer Treatment and Research Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Armed Forces and National Security

Introduced: Mar 5, 2020

Current Status: Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.

Latest Action: Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs. (Sep 23, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/6092>

Sponsor

Name: Rep. Dunn, Neal P. [R-FL-2]

Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cunningham, Joe [D-SC-1]	D · SC		Mar 5, 2020
Rep. Murphy, Gregory [R-NC-3]	R · NC		Jul 13, 2020
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Jul 13, 2020

Committee Activity

Committee	Chamber	Activity	Date
Veterans' Affairs Committee	House	Markup By	Sep 17, 2020
Veterans' Affairs Committee	Senate	Referred To	Sep 23, 2020

Subjects & Policy Tags

Policy Area:

Armed Forces and National Security

Related Bills

No related bills are listed.

Veteran's Prostate Cancer Treatment and Research Act

This bill requires the Department of Veterans Affairs (VA) to implement programs and resources related to the diagnosis and treatment of prostate cancer.

Specifically, the bill requires the VA to establish in its National Surgery Office a national clinical pathway for all stages of prostate cancer that includes specified elements. A clinical pathway is a health care management tool designed around research and evidence-backed practices that provides direction for the clinical care and treatment of a specific episode of a condition or ailment.

The VA must publish the proposed clinical pathway in the Federal Register for public comment. Additionally, the bill requires the VA to publish the established clinical pathway on a public VA website and to update the clinical pathway at least annually.

Under the bill, the VA must submit (1) a plan to establish a comprehensive prostate cancer program, and (2) a plan that provides for continual funding for supporting prostate cancer research through the VA Office of Research and Development. The VA must also establish a program evaluation tool to learn best practices of multidisciplinary disease-based implementation.

Finally, the VA must establish a real-time, actionable, national prostate cancer registry that is accessible to clinicians and researchers.

Actions Timeline

- **Sep 23, 2020:** Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.
- **Sep 22, 2020:** Mr. Takano moved to suspend the rules and pass the bill, as amended.
- **Sep 22, 2020:** Considered under suspension of the rules. (consideration: CR H4682-4685)
- **Sep 22, 2020:** DEBATE - The House proceeded with forty minutes of debate on H.R. 6092.
- **Sep 22, 2020:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- **Sep 22, 2020:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4684-4685)
- **Sep 22, 2020:** Motion to reconsider laid on the table Agreed to without objection.
- **Sep 17, 2020:** Committee Consideration and Mark-up Session Held.
- **Sep 17, 2020:** Ordered to be Reported by Voice Vote.
- **Sep 10, 2020:** Committee Hearings Held.
- **Mar 5, 2020:** Introduced in House
- **Mar 5, 2020:** Referred to the House Committee on Veterans' Affairs.